# OnCo record paper-acalabrutinib-cll-j-clin-oncol-2021 (paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/key-papers/paper-acalabrutinib-cll-j-clin-oncol-2021/>
  a schema:ScholarlyArticle ;
  onco:kind "paper" ;
  schema:identifier "paper-acalabrutinib-cll-j-clin-oncol-2021" ;
  schema:name "Acalabrutinib Versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia: Results of the First Randomized Phase III Trial"@en ;
  schema:description "Phase 2 or 3 results paper on Acalabrutinib in Chronic lymphocytic leukaemia, in Journal of Clinical Oncology (2021), one of the most cited Europe PMC records with Acalabrutinib in its title."@en ;
  schema:url <https://onco.cc/key-papers/paper-acalabrutinib-cll-j-clin-oncol-2021/> ;
  schema:dateModified "2026-09-22"^^xsd:date ;
  schema:citation <https://doi.org/10.1200/jco.21.01210>, <https://pubmed.ncbi.nlm.nih.gov/34310172/>, <https://europepmc.org/article/MED/34310172> ;
  onco:tag "europepmc-ingest" ;
  schema:sameAs <https://doi.org/10.1200/jco.21.01210> ;
  schema:datePublished "2021"^^xsd:gYear ;
  schema:author "Byrd JC, Byrd JC, Hillmen P, et al." ;
  onco:journals <https://onco.cc/journals/jco/> .